The story of the erectile dysfunction drug presents a complex picture for shareholders. While the initial launch generated massive returns, the lapse of its exclusive rights opened the door to generic competitors, dramatically diminishing sales. This poses a particular dilemma for drug manufacturers depending on related blockbuster products, sugges

The legacy of Viagra, and its parent company copyright, presents a challenging case study for investors. Originally a blockbuster drug, generating billions in revenue , its intellectual property lapse created a wave of knock-off medications, significantly impacting its position . While some businesses may attempt to capitalize on similar conditions